UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 19, 2026

60 DEGREES PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-41719**	**45-2406880**
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.	**20036**
(Address of registrant's principal executive office)	(Zip code)

(202) 327-5422
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading symbol(s)**	**Name of each exchange on which registered**
Common Stock, par value $0.0001 per share	SXTP	The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock	SXTPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On November 19, 2026, 60 Degrees Pharmaceuticals, Inc. (the "Company") received a letter (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the bid price of the Company's listed securities had closed at less than $1.00 per share over the previous 30 consecutive business days, from October 8, 2026 through November 18, 2026, and, as a result, the Company did not comply with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").

The Notice further stated that, because the Company effected a 1-for-5 reverse stock split on February 24, 2025, and a 1-for-4 reverse stock split on January 20, 2026, resulting in a cumulative reverse stock split ratio of 1-for-20, the Company has effected a reverse stock split over the prior one-year period and, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A). Accordingly, Staff has determined to delist the Company's securities from The Nasdaq Capital Market.

Unless the Company requests an appeal of Staff's determination by November 27, 2026, the Company's securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on December 1, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's securities from listing and registration on Nasdaq. The Company may appeal the Staff's determination to a Hearings Panel (the "Panel") pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. A hearing request will stay the suspension of the Company's securities and the filing of the Form 25-NSE pending the Panel's decision. In connection with a hearing, the Company will be asked to provide the Panel with a plan to regain compliance, which may include a commitment to effect a reverse stock split, if necessary.

As of the date of this current report, the Company has requested a hearing before the Panel and paid the related $20,000 hearing fee, which request will stay the suspension of trading and the filing of the Form 25-NSE pending the Panel's decision. There can be no assurance that the Panel will grant the Company's request for continued listing.

Item 7.01. Regulation FD Disclosure

In accordance with Nasdaq Listing Rule 5810(b), the Company is issuing this Current Report on Form 8-K to publicly disclose receipt of the Nasdaq staff determination letter described above.

Item 8.01. Other Events

The Company has confirmed with Nasdaq that it will effect a reverse stock split of its issued and outstanding common stock (the "Reverse Stock Split"), which is expected to become effective on December 2, 2026. The Company anticipates that its common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market under the existing trading symbol "SXTP" at the opening of trading on December 2, 2026, under a new CUSIP number. The Company is effecting the Reverse Stock Split in order to increase the per share bid price of its common stock and regain compliance with the Bid Price Rule, and intends to present the Reverse Stock Split to the Panel as part of its plan to regain compliance. Additional details regarding the Reverse Stock Split, including the split ratio and the treatment of fractional shares, will be disclosed by the Company prior to its effectiveness. There can be no assurance that the Reverse Stock Split will be effected on the anticipated date or at all, that the market price of the Company's common stock following the Reverse Stock Split will be sufficient to regain or maintain compliance with the Bid Price Rule, or that the Panel will grant the Company's request for continued listing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

60 DEGREES PHARMACEUTICALS, INC.

Date: November 20, 2026

By: */s/ Geoffrey Dow*
Name: Geoffrey Dow
Title: Chief Executive Officer and President